华大基因(300676) - 2021 Q3 - 季度财报

Financial Performance - Revenue for Q3 2021 was CNY 1,505,833,804.01, a decrease of 43.05% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 328,216,516.53, down 68.86% year-on-year[4] - Basic earnings per share decreased by 69.76% to CNY 0.8007[4] - Total operating revenue for Q3 2021 was CNY 5,152,043,496.53, a decrease of 23.6% compared to CNY 6,752,075,755.82 in Q3 2020[25] - Net profit for Q3 2021 was CNY 1,431,148,673.37, down 47.5% from CNY 2,731,943,517.21 in the same period last year[25] - Basic earnings per share decreased to CNY 3.4586 from CNY 6.7924 year-over-year[26] - The total comprehensive income for Q3 2021 was CNY 1,444,963,979.82, down from CNY 2,681,487,828.56 in Q3 2020[26] Assets and Liabilities - Total assets increased by 27.31% to CNY 14,252,521,388.15 compared to the end of the previous year[4] - Total liabilities decreased to CNY 4,875,026,974.41 from CNY 5,169,299,593.44, indicating a reduction of approximately 5.7%[23] - The total owner's equity increased to CNY 9,377,494,413.74 from CNY 6,025,740,942.15, reflecting a growth of 55.5%[23] - The company reported a current liability total of CNY 3,405,485,140.61, down from CNY 3,802,121,411.25, a decrease of 10.4%[23] - The total assets amounted to CNY 11,195,040,535.59, a slight increase of 1.4% from CNY 11,349,530,094.64 year-on-year[31] - The total liabilities were CNY 3,802,121,411.25, a decrease of 1.1% from CNY 3,845,696,187.39 in the previous year[31] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 1,755,451,570.56, a decrease of 32.46%[4] - The net cash flow from operating activities decreased by 32.46% to CNY 1.76 billion, primarily due to a reduction in cash received from sales of goods and services[8] - The net cash flow from investing activities decreased significantly by 1734.97% to CNY -1.28 billion, mainly due to increased purchases of financial products[8] - The total cash inflow from investment activities was CNY 2,343,763,844.38, down 39.6% from CNY 3,883,880,230.58 year-on-year[28] - The company reported a net cash increase of CNY 1,525,783,842.87, compared to CNY 3,313,792,552.33 in the previous year, indicating a decline of 54.0%[28] Investments and Expenditures - The company reported a significant increase in trading financial assets, reaching CNY 1,180,457,722.40, a 100% increase[6] - The company’s long-term equity investments decreased by 36.44% to CNY 134,425,847.81 due to reclassification of assets[6] - The company’s intangible assets increased by 49.52% to CNY 219,438,774.31, attributed to the acquisition of Natera's tumor gene detection technology[6] - The company’s development expenditures rose by 64.31% to CNY 53,580,079.27, reflecting ongoing investment in capitalized R&D projects[6] - Research and development expenses rose to CNY 354,898,676.34, up from CNY 256,732,082.38, indicating a focus on innovation[25] Shareholder Activities - The actual controller and chairman, Wang Jian, plans to increase his shareholding by at least RMB 50 million within six months from September 29, 2021, to March 28, 2022[14] - Shareholder Huada Investment reduced its holdings by 4,951,945 shares, representing 1.1964% of the total share capital, decreasing its stake from 9.5243% to 8.3279%[15] - Specific shareholder Heyu Gaolin reduced its holdings by 713,039 shares, accounting for 0.1723% of the total share capital, lowering its stake from 4.6929% to 4.5207%[16] - A total of 13,814,325 shares issued to specific investors became tradable on August 9, 2021, after the lock-up period ended[18] Other Financial Metrics - The company paid CNY 1,436,547,972.96 to employees, which is a significant increase of 100.1% compared to CNY 717,527,750.18 in the previous year[28] - The company reported an investment income of CNY 114,491,600.10, slightly up from CNY 108,120,271.12 in Q3 2020[25] - Other comprehensive income after tax was CNY 13,815,306.45, contrasting with a loss of CNY 50,455,688.65 in the previous year[26] - The company has invested CNY 12,500,000 in establishing a partnership for venture capital, indicating strategic expansion efforts[19] - The subsidiary Langfang BGI Jibai Biotechnology Co., Ltd. acquired 50.4195 acres of industrial land for CNY 21,400,000 to build a production base, enhancing future capacity[20]